Eris Lifesciences Limited Asset Resilience Ratio
Eris Lifesciences Limited asset resilience ratio. Eris Lifesciences Limited (ERIS) has an Asset Resilience Ratio of 0.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Eris Lifesciences Limited fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Eris Lifesciences Limited (2012–2026)
Asset resilience ratio of Eris Lifesciences Limited from 2012 to 2026. This chart shows how Eris Lifesciences Limited's Asset Resilience Ratio has changed over time. Read Eris Lifesciences Limited total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Eris Lifesciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ERIS asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs216.40 Million | 0.29% |
| Total Liquid Assets | Rs216.40 Million | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Eris Lifesciences Limited maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Eris Lifesciences Limited Industry Peers by Asset Resilience Ratio
Compare Eris Lifesciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Eris Lifesciences Limited Asset Resilience Ratio by Year (2012–2026)
Eris Lifesciences Limited asset resilience ratio by year from 2012 to 2026. The table below shows the annual Asset Resilience Ratio data for Eris Lifesciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.29% | Rs216.40 Million ≈ $2.34 Million |
Rs73.66 Billion ≈ $796.55 Million |
+0.22pp |
| 2025-03-31 | 0.07% | Rs50.00 Million ≈ $540.73K |
Rs70.33 Billion ≈ $760.61 Million |
-17.59pp |
| 2024-03-31 | 17.66% | Rs12.45 Billion ≈ $134.60 Million |
Rs70.49 Billion ≈ $762.30 Million |
+16.75pp |
| 2023-03-31 | 0.91% | Rs332.21 Million ≈ $3.59 Million |
Rs36.67 Billion ≈ $396.61 Million |
-6.26pp |
| 2022-03-31 | 7.17% | Rs1.63 Billion ≈ $17.62 Million |
Rs22.72 Billion ≈ $245.72 Million |
+6.33pp |
| 2021-03-31 | 0.84% | Rs153.99 Million ≈ $1.67 Million |
Rs18.35 Billion ≈ $198.42 Million |
-3.98pp |
| 2020-03-31 | 4.82% | Rs747.81 Million ≈ $8.09 Million |
Rs15.52 Billion ≈ $167.88 Million |
-15.45pp |
| 2019-03-31 | 20.27% | Rs3.15 Billion ≈ $34.06 Million |
Rs15.54 Billion ≈ $168.02 Million |
+13.85pp |
| 2018-03-31 | 6.42% | Rs937.89 Million ≈ $10.14 Million |
Rs14.60 Billion ≈ $157.90 Million |
-33.90pp |
| 2017-03-31 | 40.33% | Rs2.58 Billion ≈ $27.95 Million |
Rs6.41 Billion ≈ $69.32 Million |
+24.72pp |
| 2016-03-31 | 15.61% | Rs653.20 Million ≈ $7.06 Million |
Rs4.19 Billion ≈ $45.27 Million |
-3.77pp |
| 2015-03-31 | 19.38% | Rs692.40 Million ≈ $7.49 Million |
Rs3.57 Billion ≈ $38.64 Million |
-5.37pp |
| 2014-03-31 | 24.75% | Rs669.64 Million ≈ $7.24 Million |
Rs2.71 Billion ≈ $29.26 Million |
-2.32pp |
| 2013-03-31 | 27.07% | Rs465.00 Million ≈ $5.03 Million |
Rs1.72 Billion ≈ $18.58 Million |
+13.88pp |
| 2012-03-31 | 13.18% | Rs134.52 Million ≈ $1.45 Million |
Rs1.02 Billion ≈ $11.04 Million |
-- |
About Eris Lifesciences Limited
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more